Professional Documents
Culture Documents
Alan F. Eisenberg
Executive Vice President Biotechnology Industry Organization (BIO)
Local Co-Host
Conference Sponsors
2 Drugs Approved With Companion Diagnostics: Xalkori (Pfizer) NSCLC Zelboraf (Daiichi Sankyo/Plexxikon/Roche) Metastatic Melanoma Adcetris (Seattle Genetics) Lymphoma/Hodgkins Yervoy (BMS) -- Melanoma
NBI +11%
Acquired or bankrupt since 2007
New issues since 2007
Median -25%
2011
NBI +14%
New issues since 2007
Investors More Focused On Early Stage, Taking Greater Risk On Less Liquid Cos
17 12 3
# IPOs
15 10 5 0 1
This presentation may contain forward-looking statements. Actual results may differ materially from such forward-looking statements as a result of various factors involving uncertainties and risks that vary from company to company. The specific uncertainties and risks pertaining to individual publicly-traded companies at this conference should be reviewed in each companys Form 10-K report and other such documents filed with the Securities and Exchange Commission. Some companies may be clients of the Conference sponsors or members of BIO.
Opening Plenary: Picks and Pans The Buy-Side View for 2012
Moderator:
Stephen Sands - Vice Chairman of US Investment Banking and Global Co-Head of Healthcare, Lazard
Panelists: